[實習生涯][內科]血腫-RECIST 1.1

是for solid tumor 治療的評估，可能四個禮拜左右就可以評估一下吧
看Chemo的療效之類的

4.3. Response criteria
This section provides the definitions of the criteria used to determine objective tumour response for target lesions.
4.3.1. Evaluation of target lesions

Complete Response (CR):
Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <  10 mm<10mm 10="" mm.="" nbsp="" p="">


<10 mm.="" nbsp="" p="">Partial Response (PR):
At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease (PD):
At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Stable Disease (SD):
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study

關於淋巴結：就算效果超級無敵好，病變是小到量不到，也不可能消到0......應該默認有個5mm；除非放射科醫師覺得病變不見了才算0

還有non-target lesion的評估：比如pleural effusion啦淋巴管啦此略不提

<10 mm.="" nbsp="" p="">
<10 mm.="" nbsp="" p="">